News from EHA23 – A promising treatment option for follicular lymphoma
Dr. Ryan Jacobs of Levine Cancer Institute presents encouraging findings from an ongoing phase 1 trial of TNB-486, a novel CD19xCD3 T-cell engager. The study reveals a remarkable 91% complete response rate in a specific subset of relapsed refractory follicular lymphoma patients. A response who appears to be durable with a 6-month PFS rate of 91% and a median follow-up of 8 months.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.